ENGN
Price
$1.58
Change
-$0.04 (-2.45%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
109.24M
62 days until earnings call
Intraday BUY SELL Signals
PHAR
Price
$10.60
Change
+$1.12 (+11.81%)
Updated
Oct 22, 04:35 PM (EDT)
Capitalization
670.98M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ENGN vs PHAR

ENGN vs PHAR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ENGN vs. PHAR commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENGN is a Hold and PHAR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ENGN with price predictions
Oct 21, 2026

ENGN's Indicator enters downward trend

The Aroon Indicator for ENGN entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 107 similar instances where the Aroon Indicator formed such a pattern. In 94 of the 107 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENGN as a result. In 36 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

The Moving Average Convergence Divergence Histogram (MACD) for ENGN turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In 22 of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

ENGN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ENGN crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENGN's RSI Indicator exited the oversold zone, 21 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENGN advanced for three days, in 124 of 145 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

ENGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.474) is normal, around the industry mean (2.988). P/E Ratio (-0.787) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ENGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PHAR with price predictions
Oct 21, 2026

PHAR's RSI Indicator ascends from oversold territory

The RSI Oscillator for PHAR moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 13 similar instances when the indicator left oversold territory. In 12 of the 13 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where PHAR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for PHAR just turned positive on October 20, 2026. Looking at past instances where PHAR's MACD turned positive, the stock continued to rise in 46 of 61 cases over the following month. The odds of a continued upward trend are 75%.

Following a +0.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in 169 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

PHAR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for PHAR entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.481) is normal, around the industry mean (2.988). PHAR has a moderately high P/E Ratio (67.962) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.080) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (2.168) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
PHAR: Fundamental Ratings
PHAR
OUTLOOK RATING
1..100
86
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
86
PRICE GROWTH RATING
1..100
79
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENGNPHAR
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 25 days ago
86%
Bullish Trend 25 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
70%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (ENGN: $1.63 vs. PHAR: $9.48)
Brand notoriety: ENGN and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENGN: 165% vs. PHAR: 50%
Market capitalization -- ENGN: $109.24M vs. PHAR: $670.98M
ENGN [@Biotechnology] is valued at $109.24M. PHAR’s [@Biotechnology] market capitalization is $670.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENGN’s FA Score shows that 1 FA rating(s) are green while PHAR’s FA Score has 0 green FA rating(s).

  • ENGN’s FA Score: 1 green, 4 red.
  • PHAR’s FA Score: 0 green, 5 red.
According to our system of comparison, ENGN is a better buy in the long-term than PHAR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENGN’s TA Score shows that 4 TA indicator(s) are bullish while PHAR’s TA Score has 5 bullish TA indicator(s).

  • ENGN’s TA Score: 4 bullish, 6 bearish.
  • PHAR’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, PHAR is a better buy in the short-term than ENGN.

Price Growth

ENGN (@Biotechnology) experienced а +4.49% price change this week, while PHAR (@Biotechnology) price change was -1.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.04%. For the same industry, the average monthly price growth was -18.13%, and the average quarterly price growth was -15.32%.

Reported Earning Dates

ENGN is expected to report earnings on Dec 23, 2026.

PHAR is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ENGN
Daily Signal:
Gain/Loss:
PHAR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ENGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENGN has been closely correlated with TRDA. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENGN jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENGN
1D Price
Change %
ENGN100%
-2.40%
TRDA - ENGN
78%
Closely correlated
-6.81%
COGT - ENGN
48%
Loosely correlated
+0.61%
PHAR - ENGN
43%
Loosely correlated
-1.86%
INSM - ENGN
42%
Loosely correlated
-1.70%
ASBP - ENGN
36%
Loosely correlated
+1.49%
More

PHAR and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAR has been loosely correlated with ENGN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAR jumps, then ENGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
-1.86%
ENGN - PHAR
43%
Loosely correlated
-2.40%
TRDA - PHAR
42%
Loosely correlated
-6.81%
LKFT - PHAR
35%
Loosely correlated
-0.55%
LGND - PHAR
34%
Loosely correlated
+2.73%
INSM - PHAR
34%
Loosely correlated
-1.70%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BMNR23.961.14
+5.00%
BitMine Immersion Technologies Inc.
FIVN35.290.98
+2.86%
Five9
ABTS1.220.03
+2.52%
Abits Group Inc
SRG1.640.04
+2.50%
Seritage Growth Properties
ITIC290.333.69
+1.29%
Investors Title Company